These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34618246)

  • 1. ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma.
    Kubota K; Shimizu A; Soejima Y
    Ann Surg Oncol; 2022 Feb; 29(2):1449-1450. PubMed ID: 34618246
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single Institutional Study.
    Miyata T; Hayashi H; Baba H
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):903-904. PubMed ID: 32840745
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients.
    Chattopadhyay A; Wu CH; Tien YW; Lu TP
    Ann Surg Oncol; 2022 Mar; 29(3):1616-1617. PubMed ID: 34802101
    [No Abstract]   [Full Text] [Related]  

  • 4. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma.
    Jin W; Xu HX; Yu XJ; Liu L
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):571-572. PubMed ID: 30710182
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
    Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
    BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer.
    Sierzega M; Lenart M; Rutkowska M; Surman M; Mytar B; Matyja A; Siedlar M; Kulig J
    Ann Surg Oncol; 2017 Mar; 24(3):808-815. PubMed ID: 27770341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASO Author Reflections: Postoperative Carbohydrate Antigen 19-9 Levels Become a Reliable Biomarker for Establishing Intensity-Stratified Adjuvant Treatments in Pancreatic Ductal Adenocarcinoma.
    Ariake K; Okada T; Tsuchiya H; Kuboki D; Maemura K; Ichikawa H; Tachibana T; Akazawa N; Abe T; Kakita T; Oikawa M; Tsuchiya T
    Ann Surg Oncol; 2024 Jan; 31(1):548-549. PubMed ID: 37907696
    [No Abstract]   [Full Text] [Related]  

  • 8. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
    Groot VP; Wolfgang CL; He J
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Accurate Evaluation of Malignant Potential in Pancreatic Ductal Adenocarcinoma Using DUPAN-2 Level.
    Sumiyoshi T; Uemura K
    Ann Surg Oncol; 2024 Jul; 31(7):4697. PubMed ID: 38739237
    [No Abstract]   [Full Text] [Related]  

  • 10. ASO Author Reflections: R Status Is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma.
    Crippa S; Giannone F; Lena MS; Falconi M
    Ann Surg Oncol; 2021 Aug; 28(8):4613-4614. PubMed ID: 33586067
    [No Abstract]   [Full Text] [Related]  

  • 11. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASO Author Reflections: Potential Role of Circulating Biomarkers in Resected Pancreatic Adenocarcinoma.
    White MG; Tzeng CD
    Ann Surg Oncol; 2021 Aug; 28(8):4623-4624. PubMed ID: 33507452
    [No Abstract]   [Full Text] [Related]  

  • 13. ASO Author Reflections: Preceding Systemic Chemotherapy Might Provide Better Prognosis for Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology.
    Ariake K; Mizuma M; Motoi F; Unno M
    Ann Surg Oncol; 2021 Oct; 28(11):6255-6256. PubMed ID: 33634387
    [No Abstract]   [Full Text] [Related]  

  • 14. ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer.
    Nakagawa N; Yamada S; Kodera Y
    Ann Surg Oncol; 2020 Mar; 27(3):896-897. PubMed ID: 31848821
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma.
    Murthy P; Boone BA
    Ann Surg Oncol; 2020 Mar; 27(3):907-908. PubMed ID: 31823171
    [No Abstract]   [Full Text] [Related]  

  • 16. ASO Author Reflections: Rethinking Spleen Preservation in Patients with Body Pancreatic Ductal Adenocarcinoma.
    Hobeika C; Sauvanet A
    Ann Surg Oncol; 2024 Jul; 31(7):4691-4692. PubMed ID: 38649552
    [No Abstract]   [Full Text] [Related]  

  • 17. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Dec; 25(13):3994-3995. PubMed ID: 30315385
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: Improving Identification of Intraductal Papillary Mucinous Neoplasm Patients at Risk-Current Status and the Role of IPMN Molecular Biomarkers.
    Maker AV
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):818-819. PubMed ID: 30311163
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: Pancreatic Invasion is a Crucial Independent Prognostic Factor in Duodenal Carcinoma.
    Nitta N; Ohgi K; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Sasaki K; Uesaka K
    Ann Surg Oncol; 2020 Oct; 27(11):4561. PubMed ID: 32462525
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma.
    Tamburrino D; Guarneri G; Capurso G; Falconi M
    Ann Surg Oncol; 2021 Apr; 28(4):2323-2324. PubMed ID: 32929602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.